Is Ozempic Facing a Lawsuit? Yes, and Here's What the 2026 MDL Looks Like

Key Takeaways

• Ozempic and Wegovy are at the center of a federal multidistrict litigation (MDL 3094) consolidated in the Eastern District of Pennsylvania, with more than 13,000 plaintiffs as of Q1 2026.
• The core allegations are failure to warn about severe gastroparesis, ileus (intestinal blockage), and gallbladder disease.
• Novo Nordisk denies the claims and points to existing FDA-approved labeling, which mentions gastrointestinal events but not gastroparesis specifically.
• No bellwether trials have reached a jury verdict yet. The first bellwether selections were made in late 2025 and trial dates are expected in 2026 to 2027.
• Patients currently taking Ozempic are not required to stop. The FDA has not pulled the medication, and providers continue prescribing it.

Direct answer (40-60 words)

Yes, Ozempic is facing a lawsuit. As of April 2026, more than 13,000 plaintiffs have joined a federal multidistrict litigation (MDL 3094) against Novo Nordisk and Eli Lilly, alleging the drugs caused gastroparesis, intestinal blockage, and gallbladder injuries that the labels failed to disclose. Bellwether trials are scheduled but no verdicts have been reached.

Table of contents

1. The 30-second answer
2. What is MDL 3094 and why does it exist
3. The injuries plaintiffs are claiming
4. What Novo Nordisk and Eli Lilly are arguing
5. Where the litigation stands in April 2026
6. What "facing a lawsuit" means for current patients
7. Has the FDA changed its position on Ozempic
8. The label-update timeline since the litigation began
9. Should patients consider compounded semaglutide instead
10. How patients can decide whether to stay on or stop
11. FAQ
12. Sources
13. Footer disclaimers

What is MDL 3094 and why does it exist

A multidistrict litigation (MDL) is a federal procedural tool for consolidating thousands of similar lawsuits before a single judge for pretrial proceedings. MDL 3094, formally titled "In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation," was established in February 2024 by the Judicial Panel on Multidistrict Litigation. Judge Karen Marston of the Eastern District of Pennsylvania presides.

The MDL exists because individual product-liability suits filed in dozens of district courts shared common factual questions: did Novo Nordisk and Eli Lilly know about and fail to warn about specific gastrointestinal injuries? Consolidating discovery, expert depositions, and rulings on common issues saves time and reduces inconsistent rulings.

Cases consolidated in the MDL include claims against Ozempic, Wegovy, Rybelsus (all semaglutide products by Novo Nordisk), and Mounjaro and Zepbound (tirzepatide products by Eli Lilly). The MDL also covers Trulicity (dulaglutide) and a handful of other GLP-1 receptor agonists. So when people ask "is Ozempic facing a lawsuit," they're really asking about a much broader litigation that affects the entire GLP-1 class.

According to filings reported in Law360 and tracked by JPML public dockets, the case count grew from roughly 100 in early 2024 to over 13,000 by Q1 2026. Plaintiff lawyers expect the docket to keep growing as more patients identify symptoms and connect them to GLP-1 use.

The injuries plaintiffs are claiming

Plaintiffs allege three primary injury categories. Each has its own clinical literature backing the connection to GLP-1 receptor agonists.

Gastroparesis. This is the condition most associated with the Ozempic litigation in the press. Gastroparesis is a delayed-emptying disorder where the stomach loses its ability to push food into the small intestine. Symptoms include persistent vomiting, severe nausea, abdominal pain, and unintended weight loss. A 2023 study in JAMA (Sodhi et al., 2023) using a large insurance claims database reported a 3.67-fold higher risk of gastroparesis in semaglutide users compared with bupropion-naltrexone users, though the absolute risk was small.

Ileus and small bowel obstruction. Ileus is the loss of intestinal motility, sometimes severe enough to cause obstruction requiring surgery. The same 2023 JAMA analysis flagged elevated odds of bowel obstruction in GLP-1 users. The FDA added "ileus" as a postmarketing adverse reaction to the Ozempic label in September 2023 after FAERS reporting accumulated.

Gallbladder disease. GLP-1 agonists are associated with cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), particularly during periods of rapid weight loss. A 2022 meta-analysis in JAMA Internal Medicine (He et al., 2022) covering 76 trials found GLP-1 use linked to a 37% relative increase in gallbladder or biliary disease compared with controls.

Some plaintiffs also allege pancreatitis, vision loss (NAION, a rare retinal condition), and kidney injuries. These claims are less central to the MDL because the FDA already requires warnings for several of these conditions on the existing labels.

The legal theory across most filings is "failure to warn." Plaintiffs argue that the manufacturers knew, or should have known, that risks of gastroparesis and ileus were higher than the labels disclosed, and that adequate warnings would have changed prescribing patterns or patient consent.

What Novo Nordisk and Eli Lilly are arguing

Both manufacturers deny the core allegations. Their public statements and legal filings make several arguments.

The labels already warn about GI events. Ozempic's prescribing information has always listed nausea, vomiting, diarrhea, constipation, and abdominal pain as common adverse reactions. Defendants argue these warnings cover the symptom patterns plaintiffs describe.

Gastroparesis and ileus are listed in the labels. Novo Nordisk added "ileus" to the Ozempic label in late 2023 after FDA review of postmarketing reports. The current label also references delayed gastric emptying. Defendants argue this satisfies the failure-to-warn standard.

Causation is contested. Many plaintiffs have pre-existing risk factors (type 2 diabetes itself causes gastroparesis at elevated baseline rates) that complicate causation. Defendants are expected to argue that plaintiffs' symptoms are attributable to underlying disease rather than the medication.

The benefit-risk profile remains favorable. The defense will rely on the same trial data the FDA used for approval, including SUSTAIN-6 (Marso et al., NEJM 2016) for cardiovascular benefit and SURMOUNT-1 (Jastreboff et al., NEJM 2022) for weight loss benefit. They argue the demonstrated benefits outweigh the GI risks for properly selected patients.

These arguments will play out across years of expert depositions, motion practice, and eventually bellwether trials. None has been resolved at the jury level yet.

Where the litigation stands in April 2026

A snapshot of the MDL 3094 status as of Q1 2026:

The "Daubert hearings" reference is important. Daubert is the standard federal courts use to decide whether expert scientific testimony is admissible. If the judge rules plaintiffs' general-causation experts (the ones connecting GLP-1 use to gastroparesis or ileus at a population level) can testify, the MDL moves toward bellwether trials. If most expert testimony is excluded, plaintiffs' theories may not survive.

The first bellwether trials are scheduled for late 2026 at the earliest, with most legal observers expecting late 2027 or 2028 for verdicts. MDL bellwethers are picked to represent the strongest, weakest, and most representative cases. Verdicts in those cases drive settlement negotiations.

No global settlement has been announced. Novo Nordisk and Eli Lilly have not signaled willingness to settle until at least one bellwether reaches a jury.

What "facing a lawsuit" means for current patients

The litigation does not affect a current Ozempic prescription. The medication remains FDA-approved, available at retail pharmacies, and routinely prescribed.

Practical implications for patients:

The label can still change. Postmarketing reporting and ongoing litigation can prompt the FDA to require additional warnings. The September 2023 ileus warning is an example. Patients should re-read the medication guide periodically and ask the pharmacist about any updates at refill.

Insurance coverage is unaffected. Insurance carriers price coverage on FDA approval status and clinical guidelines, not on litigation status. Coverage hasn't changed because of MDL 3094.

You can join the MDL if you have a qualifying injury. If you've been diagnosed with gastroparesis, ileus, severe gallbladder disease, or other claimed injuries while taking Ozempic or another GLP-1 agonist, plaintiff law firms will evaluate cases for inclusion. There's no fee for the case evaluation; legal fees are typically contingent on settlement or verdict.

Statute of limitations applies. Most states have a 2 to 4 year statute of limitations on product liability claims, running from the date of injury or the date the patient knew (or should have known) the medication caused the injury. Patients considering joining the MDL should consult an attorney before assuming they have unlimited time.

The litigation is not a class action where you'd automatically be a member. Each plaintiff files individually, and the cases are then consolidated in the MDL.

Has the FDA changed its position on Ozempic

The FDA has not removed Ozempic from the market or restricted its use beyond existing indications. Three label-related actions have happened since 2022.

September 2023: FDA added "ileus" to the Ozempic adverse reactions label following FAERS analysis.

2024 to 2025: FDA reviewed postmarketing reports of NAION (a rare retinal condition) and suicidal ideation. The agency concluded the data did not support new label warnings for either at this time but noted the agency continues to monitor.

2025: FDA issued updated guidance on compounded GLP-1 medications, citing concerns about salt forms and unauthorized variants. This guidance is separate from the MDL but reflects regulatory attention to the broader GLP-1 marketplace.

The FDA's general position has been that Ozempic's benefit-risk profile remains favorable for type 2 diabetes patients and obese patients meeting the indication criteria. The agency has not signaled plans to require black-box warnings or withdraw approval.

The label-update timeline since the litigation began

The label additions in 2023 and 2024 came as plaintiffs' filings were rolling in. Defendants will likely argue these additions are responsive to ongoing safety surveillance, not admissions about prior inadequate warnings. Plaintiffs will argue the updates show the manufacturers had earlier knowledge they didn't disclose.

Should patients consider compounded semaglutide instead

Whether to switch from brand-name Ozempic to compounded semaglutide because of the litigation is a personal decision a patient should make with a licensed provider. The MDL itself doesn't make compounded semaglutide safer or riskier; the same active ingredient is involved.

Compounded semaglutide has its own regulatory status:

• It is not FDA-approved.
• It is prepared by state-licensed 503A or 503B compounding pharmacies in response to individual prescriptions.
• It has not undergone the same review process as Ozempic.
• It is not interchangeable with brand-name semaglutide for FDA-approval purposes.

The reasons patients consider compounded semaglutide are usually price (often $179 to $279 monthly through telehealth platforms vs $940+ retail), pen-supply reliability, or insurance coverage gaps. The MDL is rarely the deciding factor.

If a patient does decide to use compounded semaglutide, the same gastroparesis, ileus, and gallbladder risks apply because the active molecule is the same. (See our why compounded semaglutide is sometimes red for more on what to expect from a compounded vial.)

How patients can decide whether to stay on or stop

Patients reading about MDL 3094 sometimes ask whether they should stop their medication. The decision frame most clinicians use is straightforward.

Consider continuing if:

• You're tolerating the medication with manageable side effects.
• The clinical benefit (weight loss, A1C reduction, cardiovascular risk reduction) matches your treatment goals.
• You don't have new symptoms suggesting gastroparesis, ileus, or gallbladder disease.

Consider stopping (with provider guidance) if:

• You have persistent vomiting, severe abdominal pain, or symptoms of bowel obstruction.
• Imaging or endoscopy has confirmed gastroparesis or significant gallbladder disease.
• The side effects outweigh the benefits in your judgment.

Stopping abruptly without provider guidance carries its own risks. Diabetes patients can see rapid A1C rebound. Weight-loss patients commonly regain a substantial portion of lost weight (the STEP 4 trial, Rubino et al., JAMA 2021, showed roughly two-thirds of weight regained over 68 weeks after semaglutide discontinuation).

If you've already been diagnosed with one of the injuries claimed in MDL 3094, talk with your provider about alternative treatment paths and consult a product-liability attorney about whether to join the MDL.

FAQ

Is Ozempic being recalled because of the lawsuit? No. Ozempic has not been recalled. The medication is still FDA-approved, on retail pharmacy shelves, and routinely prescribed. The MDL is a civil product-liability proceeding, not a regulatory action. Recalls are decided by the FDA based on safety data, not by lawsuits.

Can I sue if I've taken Ozempic and had GI issues? Possibly. Plaintiff law firms working in MDL 3094 evaluate potential cases at no upfront cost. Eligibility usually requires a documented diagnosis of gastroparesis, ileus, gallbladder removal, or another qualifying injury, plus medical records showing GLP-1 use within the relevant time window. Statute of limitations varies by state.

How many people are suing Ozempic in 2026? As of Q1 2026, more than 13,000 plaintiffs are part of MDL 3094, which covers Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, and other GLP-1 medications. The case count is rising as more patients identify symptoms and file claims.

Have any Ozempic lawsuits been won by plaintiffs yet? No bellwether trials have reached a jury verdict as of April 2026. The first bellwether selections were made in late 2025. Trial dates are expected in late 2026 through 2028. Until verdicts come in, plaintiffs have limited settlement pressure.

Is it safe to keep taking Ozempic during the lawsuit? The FDA has not changed Ozempic's approval status or required new black-box warnings. For most patients, the benefit-risk balance their provider weighed when they started the medication has not shifted because of the litigation. Patients with concerning symptoms should talk with their provider about alternatives.

Did Novo Nordisk hide information about Ozempic side effects? That's the central plaintiff allegation, and it has not been proven in court. Novo Nordisk denies the claim. Discovery is ongoing. Internal documents may surface during MDL proceedings that affect the analysis. Until then, what's "hidden" is a contested legal question, not a settled fact.

Are compounded semaglutide products part of the lawsuit? Compounded semaglutide is not directly named in MDL 3094, which focuses on brand-name manufacturers. However, the underlying clinical concerns (gastroparesis, ileus, gallbladder disease) apply to any semaglutide formulation because the active molecule is the same.

Can I get money from the Ozempic lawsuit? Possibly, if you have a qualifying injury and the case settles or wins at trial. Mass tort settlements typically pay individual plaintiffs based on injury severity, treatment cost, and other factors. No payouts have happened yet because no trials have concluded.

What's MDL 3094? MDL 3094 is the federal multidistrict litigation that consolidates GLP-1 product-liability cases. Judge Karen Marston of the Eastern District of Pennsylvania presides. The MDL handles common discovery and pretrial issues; individual cases retain their own claims and damages.

Is the FDA going to pull Ozempic off the market? There's no signal that the FDA plans to withdraw Ozempic. The agency has added warnings (ileus, anesthesia aspiration) but maintains the benefit-risk profile is favorable. Withdrawal would require a major safety finding the agency has not announced.

Should I switch to a different GLP-1 because of the lawsuit? The MDL covers most major GLP-1 medications, so switching from Ozempic to Wegovy, Mounjaro, or Zepbound doesn't avoid the litigation issue. The clinical concerns affect the class, not just one drug. Switching usually makes sense for tolerability or insurance reasons, not litigation reasons.

How do I find out if I qualify to file? Contact a plaintiff product-liability law firm. Most offer free case evaluations. Bring your prescription history, any imaging or endoscopy reports, and your timeline of symptoms. The firm will tell you whether your case fits the MDL criteria.

Sources

1. In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, U.S. District Court for the Eastern District of Pennsylvania.
2. Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797.
3. He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2022;182(5):513-519.
4. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
5. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
6. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
7. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.
8. U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information, revised September 2023 (ileus addition).
9. American Society of Anesthesiologists. Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Agonists. 2023.
10. Judicial Panel on Multidistrict Litigation, Order Establishing MDL 3094, February 2024.
11. U.S. FDA, FAERS Public Dashboard, semaglutide adverse event reports, accessed Q1 2026.
12. U.S. FDA Guidance on Compounded GLP-1 Drug Products, 2025.
13. Law360 reporting on MDL 3094 case count and bellwether selection, late 2025 to Q1 2026.
14. American College of Gastroenterology Clinical Guideline: Management of Gastroparesis. Am J Gastroenterol. 2022.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.